Table 3.

Changes in questionnaires scores and urinary symptoms before and after 12 weeks of mirabegron treatment in patients with OAB.

	OAB before treatment	OAB after treatment	p valuea
	(n = 23)	(n = 23)
OABSSb	12.00 ± 2.97	7.52 ± 2.04	< 0.001*
OAB-qSF symptom bother	24.52 ± 6.08	13.39 ± 6.39	< 0.001*
OAB-qSF HRQL	44.48 ± 9.36	26.48 ± 12.35	< 0.001*
SF-12	32.91 ± 2.04	32.83 ± 1.53	0.775
GRAS	3.00 ± 0.00	4.43 ± 0.95	< 0.001*
Micturitions/24 h	15.65 ± 5.50	10.30 ± 3.00	< 0.001*
Urgency episodes/24 h	1.79 ± 0.84	0.45 ± 0.39	< 0.001*

Data are presented as mean ± standard deviation.

OABSS, Overactive bladder symptom score; OAB-qSF, Overactive bladder questionnaire short form; HRQL, Health-related quality of life scales; SF-12, Short Form Survey-12; GRAS, Global response assessment scale.

^aWilcoxon signed-rank test.

^bPaired t-test.

*p < 0.05.